Division of Gastroenterology and Hepatology, NYU Langone Health, New York, NY.
University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL.
Inflamm Bowel Dis. 2020 Jun 18;26(7):971-973. doi: 10.1093/ibd/izaa109.
First detected in Wuhan, China, the novel 2019 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped RNA beta-coronavirus responsible for an unprecedented, worldwide pandemic caused by COVID-19. Optimal management of immunosuppression in inflammatory bowel disease (IBD) patients with COVID-19 infection currently is based on expert opinion, given the novelty of the infection and the corresponding lack of high-level evidence in patients with immune-mediated conditions. There are limited data regarding IBD patients with COVID-19 and no data regarding early pregnancy in the era of COVID-19. This article describes a patient with acute severe ulcerative colitis (UC) during her first trimester of pregnancy who also has COVID-19. The case presentation is followed by a review of the literature to date on COVID-19 in regard to inflammatory bowel disease and pregnancy, respectively.
首例新型冠状病毒 2019(SARS-CoV-2)于 2019 年在中国武汉被发现,是一种包膜 RNAβ-冠状病毒,引发了前所未有的、全球性的 COVID-19 大流行。由于感染具有新颖性,且免疫介导疾病患者的相应高水平证据不足,因此目前 COVID-19 感染的炎症性肠病(IBD)患者的最佳免疫抑制管理基于专家意见。关于 COVID-19 感染的 IBD 患者的数据有限,而在 COVID-19 时代,关于早期妊娠的数据则没有。本文描述了一位在妊娠第一 trimester 患有急性重度溃疡性结肠炎(UC)的患者,同时患有 COVID-19。病例介绍之后,分别对迄今为止关于炎症性肠病和妊娠 COVID-19 的文献进行了回顾。